{"prompt": "['Trelagliptin-4002', 'Page 36 of 66', 'Version 1.0', 'November 2, 2016', 'Table 9.a', 'Laboratory tests', 'Serum chemistry', 'HbA1c', 'Glycoalbumin', 'Fasting blood glucose', '1,5-AG', 'Fasting insulin', 'serum creatinine', 'Fasting glucagon', 'Urinalysis', 'urinary 8-OHdG', 'Urinary creatinine', 'The principal investigator shall keep laboratory test reference values, including the historical data.', '9.1.8 The Basic Information on Study Subject (Your Basic Profile)', 'Study subjects will answer the \"Your Basic Profile\" regarding their diabetes therapy at each', 'assessment time point during the screening period and treatment period. The principal investigator or', 'investigator will provide directions to the study subjects to answer all questions truthfully, which', 'will be recorded on the CRF. Of note, in the column \"Other drugs than diabetic drugs (e.g., for', 'hypertension)\" in the \"Your Basic Profile\", drugs prescribed in a medical institution shall be', 'recorded. (Supplements and medicines for as-needed use are not included, even though it was', 'prescribed in a medical institution.)', '9.1.9 DTR-QOL Questionnaire', 'Subjects will answer the DTR-QOL Questionnaire (all 29 questions) 5) regarding the diabetes', 'therapy being conducted at each assessment time point during the screening period and treatment', 'period. The investigator will instruct the subjects to answer all questions truthfully and record the', 'scores of each question of the DTR-QOL Questionnaire (29 questions in total) on the CRF.', '[Calculation of the total score based on answers of the DTR-QOL Questionnaire]', 'Calculation method of the total score of Factor 1: \"burden on social activities and daily', 'activities\" (13 questions in all)', 'Every score of the question number 1-13 will be simply added up, and the total figure will be', 'subsequently converted to percentage [the best (91) and worst (13) scores will be equivalent to', '100% and 0%, respectively].', 'Calculation method of the total score of Factor 2: \"anxiety and dissatisfaction with treatment\"', '(8 questions in all)', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 37 of 66', 'Version 1.0', 'November 2, 2016', 'Every score of the question number 14-21 will be simply added up, and the total figure will be', 'subsequently converted to percentage [the best (56) and worst (8) scores will be equivalent', 'to', '100% and 0%, respectively].', 'Calculation method of the total score of Factor 3: \"hypoglycemia\" (4 questions in all)', 'Every score of the question number 22-25 will be simply added up, and the total figure will be', 'subsequently converted to percentage [the best (28) and worst (4) scores will be equivalent to', '100% and 0%, respectively].', 'Calculation method of the total score of Factor 4: \"treatment satisfaction\" (4 questions in all)', 'Each score of the question number 26-29 will be converted into reverse (i.e., 1 will be', 'converted to 7, 7 will be converted to 1, and so on. The converted scores, where 7 is the best', 'and 1 is the worst, have the opposite sequence of the original scores). Then, the converted', 'scores will be simply added up, and the total figure will be subsequently converted to', 'percentage [the best (28) and worst (4) scores will be equivalent to 100% and 0%, respectively].', 'Calculation method of the total score of all questions', 'Each score of the question number 26-29 will be converted into reverse, as described above,', 'and then these converted scores and original scores of the question number 1-25 will be simply', 'added up. Subsequently, the total figure will be converted to percentage [the best (203) and', 'worst (29) scores will be equivalent to 100% and 0%, respectively].', 'If some answers of a questionnaire are unavailable (i.e., missing data), the scores will be handled in', 'the manner below:', 'Factor 1-4: As for a factor associated with <50% missing data, the mean value calculated from', 'available answers will be applied to cover the missing data.', 'The total score for a factor with >50% missing data should not be calculated.', 'The total score of whole questions should not be calculated as well, if a total score of any of the four', 'factors is unavailable.', '9.1.10 DTSQ', 'Subjects will answer the DTSQ (all 8 questions) 6),7) regarding the diabetes therapy being conducted', 'at each assessment time point during the treatment period. The investigator will instruct the subjects', 'to answer all questions truthfully and record the scores of each question of the DTSQ (8 questions in', 'total) on the CRF.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 38 of 66', 'Version 1.0', 'November 2, 2016', '9.1.11 Treatment Compliance', 'Throughout the study period, instructions for treatment will be given to subjects. If instructions were', 'given for treatment incompliance, the details will be recorded on the source document. At each visit,', 'the investigator will check with subjects the treatment compliance status with study drug or', 'comparative drug.', 'The investigator will instruct the subjects to record study drug or comparative drug usage on a', '\"Diabetes Treatment Medication Record Card*. The subjects will also be instructed to bring empty', 'sheets allowing compliance and usage to be checked along with the \"Diabetes Treatment Medication', \"Record Card*' at each visit. The treatment compliance status with the study drug or comparative\", 'drug (administration time and quantity of the study drug or comparative drug prescribed and unused)', 'will be recorded on the CRF throughout the study period.', '*. Diabetes Treatment Medication Record Card: The card contains an electronic circuit board, and', 'the times that medication is taken are electronically recorded by pressing a button when medication', 'is taken.', '9.1.12 Hospitalization for type 2 diabetes', 'The investigator will check with study subjects any hospitalization for type 2 diabetes after the first', 'administration of the study drug or comparative drug (excluding educational hospitalization without', 'worsening of diabetes). The admission-discharge date will be recorded on CRF.', '9.1.13 Contraception', 'Female subjects of childbearing potential (e.g., nonsterilized or premenopausal female subjects)', 'must use adequate contraception from signing on the informed consent throughout the study period.', 'At the time of acquisition of informed consent from an applicable study subject, signature on the', 'informed consent should be acquired only after explanation is made about what is the adequate', 'contraception and that the subject must avoid to be pregnant during the study period by use of the', 'informed consent form until the subject thoroughly understands them.', '9.1.14 Pregnancy', 'When a study subject or a partner of study subject was found to be pregnant during the study period,', 'the principal investigator or investigator notify the monitoring staff of the sponsor. The principal', 'investigator or investigator provide detailed information using the Follow-up Form for Pregnancy', 'separately wherever possible.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 39 of 66', 'Version 1.0', 'November 2, 2016', '9.1.15 Record of study subjects who are withdrawn before randomization', 'A CRF shall be created for all study subjects who have signed the consent form and withdrawn', 'before randomization.', 'The following items are to be described on the CRF.', 'Date of consent obtainment', 'Date of birth', 'Gender', 'Eligibility', 'Reason for discontinuation', 'The primary reason for withdrawal before randomization shall be recorded on the CRF according to', 'the following classification:', 'Not satisfying at least one of the inclusion criteria or meeting any of the exclusion criteria', 'Major protocol deviation', 'Lost to follow-up', 'Voluntary discontinuation (specify the reason)', 'Study termination', 'Pregnancy', 'Others (specify the reason)', 'Study subject ID codes assigned to study subjects withdrawn from the study before randomization', 'shall not be reused.', '9.1.16 Record of randomization', 'Study subjects to be randomized shall meet all of the inclusion criteria and shall not meet any of the', 'exclusion criteria according to Section 8.4. The principal investigator or investigator shall specify', 'the primary reason why the study subject cannot be randomized.', '9.2', 'Implementation time point of the tests and observation', 'The schedule for all tests, observations, and evaluations is shown in Appendix A. The principal', 'investigator or investigator shall perform the tests, observations, and evaluations at the time points', 'shown below.', '9.2.1 Screening period (Week -4)', 'After obtaining informed consent, the physical examination and tests will be performed for the', 'determining eligibility for study enrollment. The eligibility of a patient will be determined based on', 'the inclusion/exclusion criteria presented in the section 7.0. Refer to the section 9.1.16 for the', 'preparation of records on a study subject withdrawn from the study before randomization.', 'CONFIDENTIAL']", "completion": ""}